We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.55 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
25/5/2018 16:14 | Nice big buy on my heals as well, roll on next week and Trump saying something nice :) | rathean | |
25/5/2018 15:47 | That's me back in at 30.6, remarkable price considering the stage this pharma is at. | rathean | |
25/5/2018 08:04 | I am a bit wary of CROs, having done some work for one of them, and having experienced things in the sector. I would imagine we are using a CRO or another consultancy for this submission to the FDA and the consultants will be trying to get as much money as possible out of this. I know that we need to get it 'right', but in the end, the FDA/EMA are actively encouraging new antibiotics, to refuse it because something is in the wrong font, there are two spaces after full stops rather than one (I have some experience of medical writing) and trivial stuff like that, or because something is missing, needs more analysis and they will not accept the information later, would be a PR disaster for the people working at the FDA/EMA. So please get the submission in, don't worry about all the finer details, fulfilling the basic requirements are the important things. Provide the evidence that it has gone through trials, it is safe and equally efficacious to vancomycin in ABSSSI, with potentially less renal side effects. Ask what the expert reviewers would want to see, check it is in the submission, and send it off. Health services need iclaprim as another alternative. And it is then for us to decide what price we (would like to) charge and how we pitch it in the market, in negotiations later of course, but get it approved!! | gclark | |
24/5/2018 08:00 | Interesting that AMP offloaded 2.9999% to US investor. Those Yanks aren't normally shy retiring types that like to keep under the radar for no good reason...... | blueblood | |
23/5/2018 08:55 | You will have a bloody long wait then! | blueblood | |
23/5/2018 08:55 | These streets are paved with gold. | encarter | |
23/5/2018 08:52 | No. Waiting for blood in the streets. | pretax2 | |
23/5/2018 08:37 | Just here for fun then? | small crow | |
23/5/2018 08:31 | In MTFB? I’m not investing | pretax2 | |
23/5/2018 08:29 | If you think its inconsequential maybe you shouldn't be investing... | blueblood | |
23/5/2018 07:46 | This is good news, at least we don't have to worry about AMP dumping shares on the open market which indeed would have been a major drag on the share price. Selling to a US investor should give us a much needed lift. | t-trader | |
23/5/2018 07:44 | AMP are selling because they need the cash and had a chance to sell a big chunk of their stock which they would have trouble dumping onto the market. Let's hope they find a buyer for the rest and F OFF. | encarter | |
23/5/2018 07:27 | Good news that AMP have sold big chuck to US investors | blueblood | |
23/5/2018 07:21 | Interesting that a US investment house has taken a big chunk here, they can see the upside from these prices. | rathean | |
22/5/2018 17:52 | Surely we will get news that the NDA has been submitted to the FDA any day now | return_of_the_apeman | |
22/5/2018 17:24 | It's a puzzle for sure. Could it be Sandgrove accumulating again? | kspine | |
22/5/2018 16:51 | Why would anyone sell nearly 9m shares at placing price? | blueblood | |
21/5/2018 15:27 | Ŕeturned to the placing price so have picked up some more | return_of_the_apeman | |
21/5/2018 13:22 | Except for the share price itself... | rizler | |
21/5/2018 11:52 | Think I worked out support at about 30p. If it holds, company has prob with cash burn. | pretax2 | |
21/5/2018 09:04 | That's me in with a nibble of 17500. Support at these levels, well funded with FDA approval in Q2 of this year after 2 successful phase 3 trials. | rathean |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions